Gruppo Oncologico del Nord-Ovest
Quick facts
Marketed products
Phase 3 pipeline
- docetaxel - cisplatin - 5-fluorouracil · Oncology
Docetaxel inhibits microtubule dynamics, disrupting cell division, while cisplatin induces DNA crosslinks, and 5-fluorouracil inhibits thymidylate synthase. - L-leucovorin · Oncology
L-leucovorin is a reduced folate that enhances the cytotoxic activity of fluorouracil by stabilizing the ternary complex between fluorodeoxymonophosphate, thymidylate synthase, and the reduced folate cofactor.
Phase 2 pipeline
- Pembolizumab · Other
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Gruppo Oncologico del Nord-Ovest portfolio CI brief
- Gruppo Oncologico del Nord-Ovest pipeline updates RSS
Frequently asked questions about Gruppo Oncologico del Nord-Ovest
What are Gruppo Oncologico del Nord-Ovest's marketed drugs?
Top marketed products include Leucovorin and 5-FU.
What is Gruppo Oncologico del Nord-Ovest's pipeline?
Gruppo Oncologico del Nord-Ovest has 2 drugs in Phase 3, 1 in Phase 2, 0 in Phase 1. Late-stage candidates include docetaxel - cisplatin - 5-fluorouracil, L-leucovorin.
Related
- Leucovorin and 5-FU
- Sector hub: All tracked pharma companies